Updating results

389 results

Sort: Relevance | Date

Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355

In development [GID-TA10321] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with epacadostat for untreated malignant melanoma ID1423

In development [GID-TA10330] Expected publication date: TBC

Technology appraisal guidance In development

Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147

In development [GID-TA10343] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

In development [GID-TA10165] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]

In development [GID-TAG410] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]

In development [GID-TAG405] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

In development [GID-TAG406] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (brain metastases) - etirinotecan pegol [ID881]

In development [GID-TA10066] Expected publication date: TBC

Technology appraisal guidance In development

Clostridium difficile associated diarrhoea - tolevamer [ID378]

In development [GID-TAG389] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

In development [GID-TA10148] Expected publication date: TBC

Technology appraisal guidance In development

Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]

In development [GID-TAG369] Expected publication date: TBC

Technology appraisal guidance In development

Head and neck cancer - contusugene ladenovec [ID76]

In development [GID-TAG407] Expected publication date: TBC

Technology appraisal guidance In development

Renal cell carcinoma (second line metastatic) - pazopanib [ID70]

In development [GID-TAG398] Expected publication date: 01 January 2011

Technology appraisal guidance In development

Pacritinib for treating myelofibrosis [ID880]

In development [GID-TA10133] Expected publication date: TBC

Technology appraisal guidance In development

Osteoarthritis - naproxcinod [ID417]

In development [GID-TAG426] Expected publication date: TBC

Technology appraisal guidance In development

Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

In development [GID-TA10154] Expected publication date: TBC

Technology appraisal guidance In development

Kidney transplantation (rejection) - belatacept [ID87]

In development [GID-TAG239] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism - apixaban (acute medical illness) [ID310]

In development [GID-TAG419] Expected publication date: TBC

Technology appraisal guidance In development

Hypercholesterolemia - mipomersen [ID524]

In development [GID-TAG437] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]

In development [GID-TAG404] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small cell) - afatinib [ID357]

In development [GID-TAG422] Expected publication date: TBC

Technology appraisal guidance In development

Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413

In development [GID-TA10329] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357

In development [GID-TA10322] Expected publication date: TBC

Technology appraisal guidance In development

Moxetumomab pasudotox for hairy-cell leukaemia [ID1142]

In development [GID-TA10288] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

In development [GID-TA10295] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264

In development [GID-TA10365] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

In development [GID-TA10473] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

In development [GID-TA10474] Expected publication date: TBC

Technology appraisal guidance In development

Avelumab for previously treated platinum-resistant ovarian cancer ID1497

In development [GID-TA10404] Expected publication date: TBC

Technology appraisal guidance In development

Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab ID1487

In development [GID-TA10437] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer [ID1513]

In development [GID-TA10419] Expected publication date: TBC

Technology appraisal guidance In development

Apalutamide for treating metastatic hormone-sensitive prostate cancer [ID1534]

In development [GID-TA10423] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma ID1470

In development [GID-TA10354] Expected publication date: TBC

Technology appraisal guidance In development

Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

In development [GID-TA10337] Expected publication date: 19 February 2020

Technology appraisal guidance In development

Nivolumab with radiation therapy for untreated glioblastoma ID1562

In development [GID-TA10443] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997

In development [GID-TA10382] Expected publication date: TBC

Technology appraisal guidance In development

Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

In development [GID-TA10480] Expected publication date: TBC

Technology appraisal guidance In development

L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

In development [GID-TA10452] Expected publication date: TBC

Technology appraisal guidance In development

Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

In development [GID-TA10502] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

In development [GID-TA10546] Expected publication date: TBC

Technology appraisal guidance In development

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

In development [GID-TA10390] Expected publication date: TBC

Technology appraisal guidance In development

Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186

In development [GID-TA10289] Expected publication date: TBC

Technology appraisal guidance In development

LJ TEST

In development [GID-TA10462] Expected publication date: TBC

Technology appraisal guidance In development

Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

In development [GID-TA10377] Expected publication date: TBC

Technology appraisal guidance In development

Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455

In development [GID-TA10356] Expected publication date: TBC

Technology appraisal guidance In development

Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

In development [GID-TA10353] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

In development [GID-TA10070] Expected publication date: TBC

Technology appraisal guidance In development

Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

In development [GID-TA10109] Expected publication date: TBC

Technology appraisal guidance In development

Renal cell carcinoma - sunitinib [ID1076]

In development [GID-TA10166] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

In development [GID-TA10151] Expected publication date: TBC

Technology appraisal guidance In development